Zai Lab Limited (ZLAB) and Novocure (NVCR) announced the LUNAR study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in overall survival over standard therapies alone. The LUNAR study is a randomized study evaluating the safety and efficacy of Tumor Treating Fields together with standard therapies for stage 4 non-small cell lung cancer following progression.
Tumor Treating Fields or TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
Novocure plans to file a Premarket Approval application with the FDA in the second half of 2023. Novocure also plans to file for a CE Mark in the European Union concurrently with the FDA submission.
For More Such Health News, visit rttnews.com.
Shares of Novocure are up 68% in pre-market trade on Thursday.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.